COCP

CocrystalA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$2.20

+109.5% vs current

Most likely

Base case

45%

Probability

Target price

$1.10

+4.8% vs current

B-

Bear case

30%

Probability

Target price

$0.50

-52.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

This was a T+3 earnings follow-up, and the key company source landed on May 15, 2026 rather than on the queue’s May 13 reference date. The release was modestly constructive operationally but not thesis-changing financially: revenue reflected a small SBIR payment, loss was roughly flat year over year, and cash declined sequentially. I did not find trustworthy post-print analyst target revisions or a well-sourced market-reaction narrative in the checked materials, so the read-through remains a cautious monitoring view rather than a confirmed positive turn.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventPhase 1b norovirus study advances into prevention and treatment cohortsHigh impact

The May 15, 2026 business update said the first cohort in the CDI-988 Phase 1b challenge study was fully enrolled and the prevention and treatment cohorts had begun enrollment, keeping the next meaningful inflection tied to a later efficacy and safety signal on symptom reduction and viral shedding rather than to this quarter’s financial print [#10-Q-2026-05-15].

2026-12-31catalystRunway and financing pressure remain the most immediate stock driverHigh impact

First-quarter results showed unrestricted cash of $4.7 million at March 31, 2026, working capital of $3.7 million, and net cash used in operations of $2.3 million for the quarter, while the 2025 10-K already carried going-concern language; that keeps a financing, partnership, or program-prioritization decision as the clearest near-term catalyst and dilution risk [#10-Q-2026-05-15][#10-K-2026-03-31].

2026-12-31catalystCDI-988 retains strategic upside if early clinical and regulatory momentum holdsHigh impact

Cocrystal’s April 30, 2026 8-K highlighted CDI-988’s mechanism of action and clinical advancement at ICAR 2026, which supports scientific visibility around the lead norovirus asset, but this remains a secondary thesis support until human efficacy data or a clearer partnering outcome emerges [#8-K-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology